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Background: Cancer is an extremely heterogeneous group of diseases traditionally categorized according to tissue
of origin. However, even among patients with the same cancer subtype the cellular alterations at the molecular
level are often very different. Several new therapies targeting specific molecular changes found in individual
patients have initiated the era of personalized therapy and significantly improved patient care. In metastatic
colorectal cancer (mCRC) a selected group of patients with wild-type KRAS respond to antibodies against the
epidermal growth factor receptor (EGFR). Testing for KRAS mutations is now required prior to anti-EGFR treatment,
however, less sensitive methods based on conventional PCR regularly fail to detect KRAS mutations in clinical
samples.
Methods: We have developed sensitive and specific assays for detection of the seven most common KRAS
mutations based on a novel methodology named Competitive Amplification of Differentially Melting Amplicons
(CADMA). The clinical applicability of these assays was assessed by analyzing 100 colorectal cancer samples, for
which KRAS mutation status has been evaluated by the commercially available TheraScreenW KRAS mutation kit.
Results: The CADMA assays were sensitive to at least 0.5% mutant alleles in a wild-type background when using
50 nanograms of DNA in the reactions. Consensus between CADMA and the TheraScreen kit was observed in 96%
of the colorectal cancer samples. In cases where disagreement was observed the CADMA result could be confirmed
by a previously published assay based on TaqMan probes and by fast COLD-PCR followed by Sanger sequencing.
Conclusions: The high analytical sensitivity and specificity of CADMA may increase diagnostic sensitivity and
specificity of KRAS mutation testing in mCRC patients.
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Cancer is the result of a somatic microevolution in
which cells acquire specific growth advantages through a
stepwise accumulation of mitotically heritable changes
in the function of cancer related genes, which may be
oncogenes, tumor suppressor genes, and DNA repair
genes. Most cancers are extremely complex at the mo-
lecular level, and two patients suffering from the same
cancer disease may have acquired very different cellular
alterations. Consequently, there is a huge potential in* Correspondence: lasse@hum-gen.au.dk
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distribution, and reproduction in any mediumindividualizing patient treatment using molecular bio-
markers as predictors for response or non-response to
targeted therapy.
New therapies targeting specific molecular changes in
tumors of individual patients have started to introduce a
paradigm shift for cancer treatment. Most cancer patients
are now tested for one or more molecular biomarkers in
order to determine optimal treatment strategies for the
individual patient [1].
Activating somatic mutations in the KRAS oncogene is
an example of a biomarker, which predicts non-response
to therapies targeting the epidermal growth factor recep-
tor (EGFR) in metastatic Colorectal Cancer (mCRC)
[2,3]. EGFR and KRAS are part of the same signalingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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KRAS mutations contribute to development and pro-
gression of several human cancers, including CRC. An
important feature of mutant KRAS is its ability to
transmit growth promoting signals independent of EGFR
activation. This is the biological explanation why anti-
EGFR treatment fails to inhibit progression of KRAS
mutated tumors. Activating mutations in KRAS are most
often found in a mutation hotspot comprising codon 12
and 13 of exon 2. Therefore, the U.S. Food and Drug
Administration (FDA) and the European Medicines
Agency (EMA) require that patients are tested for
KRAS hotspot mutations prior to anti-EGFR treatment
using the approved drugs, panitumumab and cetuximab.
However, evidence is present that patients harboring the
codon 13 c.38 G > A mutation may benefit from anti-
EGFR treatment [4,5].
We have recently evaluated several methods for the
detection of KRAS mutations in clinical samples. The
frequency of mutated samples was found to be in-
fluenced by the analytical sensitivity of the method ap-
plied [6]. In particular, conventional PCR followed by
high-resolution melting (HRM) or sequencing failed to
detect mutations in a substantial number of samples due
to the limited sensitivity of this approach. This may, in
part, be caused by intra tumor heterogeneity and con-
tamination with wild-type DNA from normal cells,
which typically are observed in infiltrating cancers. We also
evaluated a commercially available kit, the TheraScreenW
KRAS mutation kit (QIAGEN, Hilden, Germany), and an
assay based on fast COLD-PCR, which enriches for mutant
sequences by using a lower denaturation temperature in
the PCR [7]. These methods are more sensitive, and were
capable of identifying additional mutated samples not
detected by conventional PCR. However, fast COLD-PCR
failed to increase the sensitivity of melting temperature
retaining mutations, and the TheraScreen kit is more time-
consuming and less cost-effective compared to HRM fol-
lowed by sequencing of positive samples [8].
Therefore, we have developed a new method, Com-
petitive Amplification of Differentially Melting Ampli-
cons (CADMA), which enables very sensitive mutation
detection regardless of the melting properties of the
mutations to be detected [9].
In this contribution, we have designed and optimized
CADMA assays for the seven most common KRAS exon
2 hotspot mutations. The sensitivity and specificity of
each assay were evaluated using serial dilutions of cell
line DNA containing the relevant mutations in a wild-
type background. We further evaluated the potential of
these assays for the detection of KRAS mutations in
CRC samples derived from formalin fixed paraffin em-
bedded (FFPE) tissues. In total, we have tested 100 sam-
ples using the CADMA assays, and compared theseresults with results obtained using the TheraScreenW
KRAS mutation kit, which tests for the same seven
mutations. Samples, which did not give the same result
by CADMA and the TheraScreen kit, were tested using
a previously published highly sensitive TaqMan based
assay [10] and by fast COLD-PCR followed by Sanger
sequencing.
Methods
Samples and DNA extraction
Formalin-Fixed Paraffin Embedded (FFPE) blocks from
surgical biopsies from 100 patients diagnosed with
adenocarcinoma in colon were selected from the archives
at the Department of Pathology, Aarhus University
Hospital. The specimens were up to 10 years old. For
each sample, six tissue sections of 10 μm were used for
DNA extraction. Deparaffinization and DNA extraction
were performed as previously described [6].
DNA from peripheral blood (PB) obtained from medical
students were used as wild-type controls. The DNA was
extracted following a modified salt precipitation protocol
as previously described [11]. The DNA was taken from a
biobank for which informed consent was provided for
each sample. The approval by the regional ethics comity
has the journal number 2001–2.0/37.
The Local Ethical Committee, Aarhus County, Denmark,
approved this study.
Cell lines and dilution series
Seven different cell lines each containing different KRAS
mutations were used in this study; A549 (c.34 G > A,
codon 12), DLD-1 (c.38 G > A, codon 13), LS174T
(c.35 G > A, codon 12), NCI-H23 (c.34 G > T, codon 12)
PSN-1 (c.34 G > C, codon 12), RPMI 8226 (c.35 G > C,
codon 12), and SW480 (c.35 G > T, codon 12). The cell
lines were cultured and harvested, and the DNA was
extracted as described [6], with the exception of PSN-1
for which extracted DNA was purchased from Health
Protection Agency Culture Collection, UK, and NCI-
H23 for which extracted DNA was kindly donated by
Professor Dmitri Loukinov, NIAID/NIH.
DNA from each cell line was quantified using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and serially diluted
into wild-type DNA to the following fractions of mutated
alleles in a wild-type background; 50%, 10%, 1%, and
0.5% (assuming no pipetting errors and that all cell lines
are monoclonal).
CADMA primer design
The primer sequences were designed to target the KRAS
sequence obtained from GenBank [http://www.ncbi.nlm.
nih.gov/GenBank/] (KRAS GenBank accession number
NM_033360.2). Mutation specific primers were designed
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These primers each introduce two melting temperature
decreasing mutations. The overlapping primer and the
common primer were designed to avoid pseudogene
amplification and were the same for all assays. The pri-
mers for detection of the c.35 G > C mutation has been
published previously [9]. Primer sequences can be found
in Table 1.PCR and HRM Conditions for the CADMA assays
PCR cycling and HRM analysis were performed on the
Rotor-Gene 6000TM (Corbett Research, Sydney, Australia)
or the Rotorgene Q (Qiagen, Hilden, Germany). SYTOW
9 (Invitrogen, Eugene, USA) was used as intercalating
dye. The final reaction mixtures consisted of 50 ng of
DNA, 1x PCR buffer, 2.5 mmol/L MgCl2, optimized rela-
tive primer concentrations (Table 1), 200 μmol/L of each
dNTP, 5 μmol/L of SYTOW 9, 0.5U of HotStarTaq (Qia-
gen) (5U/μL) in a volume of 20 μL. The CADMA cycling
protocol was initiated by one cycle at 95°C for 15 min,
followed by 45 cycles of 95°C for 10 s, annealing
temperature (TA) for 20 s (Table 1), 72°C for 20 s, and
one cycle at 95°C for 1 min. HRM was performed from
65°C to 95°C with a temperature increase of 0.1°C/s.
Samples were analyzed in triplicates (cell line experi-
ments) or in duplicates (colorectal cancer specimens).CADMA data analysis
The Rotorgene 6000 Series Software version 1.7.87
supplied with the instrument was used to analyze the data.
When analyzing the mCRC samples, standards containing
1% mutant alleles were used as cut-off point to facilitate
direct comparison with the TheraScreenW kit. The sam-
ples were scored manually by visual inspection of the
derivative of the raw data (melt curve analysis) and the
normalized HRM and difference graphs (high resolution
melting analysis). For the difference graphs a wild-type
sample was selected as reference. The samples were
tested with each of seven CADMA assays, however,
when a sample was found to be mutation positive it
was not tested using the remaining CADMA assays unless
the result was in disagreement with the result provided by
the TheraScreen kit.Mutation analysis using the TheraScreenW KRAS
mutation Kit
The mCRC samples were analyzed using the TheraScreenW
KRAS mutation kit (Qiagen). This kit analyzes the muta-
tion status for the seven most commonly found KRAS
exon 2 mutations by a technology that combines ARMSW
(allele specific PCR) with ScorpionsW real-time PCR. The
manufacturer has reported the sensitivity to be 1%mutant alleles in a wild-type background if sufficient
DNA input is used.
Alelle-specific PCR (TaqMan)
The TaqMan based allele-specific PCR assay used herein
has been published recently by Lang et al. [10]. We used
the same PCR conditions and real-time PCR instrument
as described. This assay determines mutation status using
a predetermined cutoff ΔCt value (Ct [allele-specific assay] –
Ct [reference assay]) as described [10]. The analytical
sensitivity of the assays were reported to be 1% mutant
alleles in a wild-type background [10]. Samples were
analyzed in duplicates for all TaqMan experiments and
the average Ct value of the duplicates was used to calculate
ΔCt values.
COLD-PCR followed by Sanger sequencing
The COLD-PCR was essentially performed as previously
described [6]. However, only 10 standard PCR cycles
were performed prior to the COLD-PCR cycles using a
critical temperature of 78°C. Sanger sequencing was per-
formed using M13 tagged primers to create a longer
amplicon, which could be successfully sequenced as
previously described [6]. The COLD-PCR assay could
detect 0.5% DNA from the A549 cell line diluted in
wild-type DNA, and 1% DNA from the LS174T cell
line diluted in wild-type DNA (data not shown).
Results
The analytical sensitivity of the CADMA assays for the
detection of KRAS hotspot mutations
The CADMA assays were optimized to avoid false
amplification from wild-type sequences by the mutation
specific primer, while maintaining a high sensitivity as
previously described [9]. Hereafter, the sensitivity and
specificity was evaluated by analyzing ten wild-type repli-
cates together with a standard dilution series of mutant
alleles into wild-type alleles (50%, 10%, 1%, and 0.5%) in
triplicates. All three replicates of the 0.5% standard could
be distinguished from all ten wild-type replicates in all
assays (Figure 1).
To assess in between run variation, we repeated each
of these experiments using the Rotorgene Q (Qiagen,
Hilden, Germany) in a different laboratory. Again, the
three replicates of the 0.5% standard could all be distin-
guished from ten wild-type replicates in all assays, and
no false amplification in wild-type reactions was
observed (Additional file 1: Figure S1).
KRAS hotspot mutation analysis in CRC samples using
CADMA and the TheraScreenW KRAS mutation Kit
One-hundred mCRC samples derived from FFPE tis-
sues were analyzed for KRAS mutations using the
CADMA assays and the TheraScreenW kit. One and
Table 1 Details of the CADMA assays
Mutation Cell line Primers (introduced mutations are underlined) Primer concentrations Annealing temperature
c.34 G > A A549 Mutation specific forward: 400 nM 57°C
GAATATAAACTTATGGTAGTTGGAGATA
Overlapping forward: 100 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.34 G > T NCI-H23 Mutation specific forward: 400 nM 60°C
GAATATAAACTTGTAGTAATTGGAGCTT
Overlapping forward: 150 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.34 G > C PSN1 Mutation specific forward: 400 nM 60°C
GAATATAAACTTGTAGTAATTGGAGCTC
Overlapping forward: 100 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.35 G > A LS174T Mutation specific forward: 400 nM 60°C
GAATATAAACTTGTGGTAATTGGAGATGA
Overlapping forward: 150 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.35 G > T SW480 Mutation specific forward: 400 nM 64°C
GAATATAAACTTGTAGTAATTGGAGCTGT
Overlapping forward: 150 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.35 G > C RPMI8226 Mutation specific forward: 400 nM 58°C
GAATATAAACTTGTAGTAATTGGAGCTGC
Overlapping forward: 100 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
c.38 G > A DLD-1 Mutation specific forward: 400 nM 62°C
AAACTTGTGGTAGTTGGAGATGGTTA
Overlapping forward: 150 nM
ATGACTGAATATAAACTTGTGGTAGTTG
Common reverse: 400 nM
ACTGTCAAGGCACTCTTGCCTAC
Primer sequences are given in 5’→ 3’ directions.
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Figure 1 The analytical sensitivity and specificity of the CADMA assays performed using the Rotorgene 6000. Ten wild-type replicates
were run together with a standard dilution series of mutant alleles from cell lines carrying the relevant mutations in a wild-type background
(50%, 10%, 1%, and 0.5%) in triplicates. The three replicates of the 0.5% standard could all be distinguished from ten wild-type replicates in all
assays. A. The c.34 G > A CADMA assay. B. The c.38 G > A CADMA assay. C. The c.35 G > A CADMA assay. D. The c.34 G > C CADMA assay.
E. The c.35 G > T CADMA assay. F. The c.34 G > T CADMA assay.
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the TheraScreenW kit, respectively. These samples were
scored as “no data”. Using the TheraScreen kit 45/98
(45.9%) of the samples were found to carry a KRAS exon
2 mutation. Using CADMA 44/99 (44.4%) of the samples
were mutation positive. Consensus between the two
methods was found in 93/97 (95.9%) of the samples. The
results are summarized in Additional file 2: Table S1.
Examples from the c.34 G > T CADMA assay are
shown in Figure 2. Since the overlapping CADMA
primer amplifies both mutated and wild-type sequences
each CADMA assay may detect KRAS mutations other
than the one targeted by the mutation specific primer
albeit at a lower sensitivity. The shape of the melting
curves could easily be used to distinguish the mutation,
targeted by each CADMA assay, from other mutations
detected by the overlapping primer, as the resulting
amplicons have different melting properties, due to the
two additional mutations incorporated by the mutation
specific primer. Examples of this are shown in Figure 2.
When samples amplify late this may cause the melting
curves to be shifted [12], and other abnormalities, such
as the one shown for sample ID 69 in Figure 2, may also
result in deviations of the melting curves. Shifted melting
curves may result in differences in the normalized HRM
and difference graphs, which could lead to wrong inter-
pretation of the results, if the melting curves are not
inspected.
When testing DNA samples derived from FFPE tissues
more variation in the melt curves is likely to be observed
compared to DNA samples of high quality [9]. For this
reason, it is also important to analyze the samples of
unknown mutation status relative to standards of
known ratios of wild-type to mutant alleles. Generally,
the wild-type samples showed more variation in the
c.38 G > A CADMA assay compared to any of the
other CADMA assays (Figure 3). However, this did not
give rise to misclassification of any of the samples, and
the wild-type status of sample ID 10 and 12 shown in
figure 3 could be confirmed by COLD-PCR followed
by sequencing (data not shown). However, sample ID
2 was shown to contain a c.37 G > A and a c.39 C >
G mutation, which are not tested for by the TheraScreen
kit and CADMA. These mutations are likely to be present
at very low levels as they were found only when sequen-
cing in the forward direction, or alternatively they may be
sequencing errors.
Confirmation of the CADMA results by TaqMan and by
COLD-PCR followed by sequencing
The four samples, not providing the same result for both
methods, were tested using a previously published TaqMan
based assay [10] and by fast COLD-PCR followed by
sequencing. For sample ID 73 the TheraScreen kit waspositive for the c.35 G > A mutation, and negative
by CADMA. Sample ID 65 was positive for the
c.34 G > A mutation and the c.35 G > C mutation
by the TheraScreen kit, and only positive for the
c.35 G > C mutation by CADMA. Sample ID 91 was
positive for the c.35 G > A mutation by the TheraScreen kit
and the c.38 G > A as well as the c.35 G > A mutation by
CADMA. Finally, sample ID 96 was positive for the
c.34 G > T mutation by the TheraScreen kit and the
c.34 G > T and c.35 G > A mutations by CADMA.
The CADMA results were confirmed by the TaqMan
assay for all four samples. When using the COLD-PCR
assay the CADMA and TaqMan results were confirmed
for sample ID 65, 73, and 96. In sample ID 91, the c. 38 G
> A mutation detected by CADMA and TaqMan was con-
firmed, however, the c.35 G > T mutation detected by
CADMA, TaqMan, and the TheraScreen kit was not
detected by COLD-PCR (Additional file 2: Table S1).
Discussion
Screening for well-characterized point mutations pre-
dicting response or non-response to targeted therapies
has in recent years become widely implemented in cli-
nical settings. However, conventional PCR followed by
Sanger sequencing, pyrosequencing, or HRM analysis
may often fail to identify mutations in samples with a
substantial wild-type DNA content [6,13,14]. It has also
been shown that increased detection sensitivity may be
used to identify additional patients which do not
respond to anti-EGFR treatment [14]. For this reason,
there is an increasing need for sensitive, reliable, and
cost-effective methods for the detection of known
mutations.
We have developed assays for detection of the seven
most common KRAS mutations based on our recently
developed method named Competitive Amplification of
Differentially Melting Amplicons (CADMA), which may
be combined with COLD-PCR to further increase the
sensitivity of the assay [9]. However, clinical decision
making based upon very low prevalence KRAS muta-
tions is controversial, as it has not yet been clarified how
mutation heterogeneity within CRC tumours affects
outcome in patients treated with EGFR antibodies.
Therefore, we decided not to combine the CADMA
assays with COLD-PCR in the present study. Neverthe-
less, the analytical sensitivities of all assays were at least
0.5% mutant alleles in a wild-type background. These
results were confirmed in another laboratory. However,
it could be observed that the separation between the
cell line dilutions and the wild-types were more pro-
nounced in some runs than others, indicating that some
in between run variation may occur. In between run
variation is most likely to be caused by varying primer
concentrations in the master mixes, which were
Figure 2 (See legend on next page.)
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Figure 2 Examples from screening of mCRC samples using the c.34 G > T CADMA assay. A. Real-time amplification data. High background
fluorescence can be observed for sample ID 69. B. The derivative of the raw melting data (melt curve analysis). Sample ID 56 carry the c.34 G > T
mutation. Sample ID 2, 69 and 72 were negative for the c.34 G > T mutation. Sample ID 69 and 72 may carry another KRAS mutation as small
deviations from the wild-type replicates can be observed. Sample ID 69, which gave high fluorescence during the PCR amplification, has
deviating melt curves from 82 to 88°C. C. Normalized HRM difference graph. Of the mCRC samples shown only one (sample ID 56) deviates more
from the wild-type replicates than the standard containing 1% mutant alleles.
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the instruments.
We did not assess the analytical sensitivity of the com-
mercially available TheraScreen kit, which has been
reported by the company to be sensitive to 1% mutant
alleles in a wild-type background. However, it has
been reported that diagnostic samples derived from
FFPE tissues often may not be analyzed at this level of
sensitivity [15]. Nevertheless, we have recently shown
that the TheraScreen kit can detect mutations in sam-
ples derived from FFPE tissues, which could not
be detected by conventional PCR followed by HRM or
sequencing [6].
Here, we have analyzed mCRC samples from 100
patients using the TheraScreen kit and the CADMA
assays. To facilitate direct comparison between the two
methods, the samples were analyzed at 1% mutant level
when using CADMA. Overall, consensus between the
two methods was very high (95.9%), and in four out of
four cases where different results were observed, the
CADMA result could be confirmed by a previously pub-
lished TaqMan based assay, which is sensitive to about
1% mutant alleles in a wild-type background [10], and
by COLD-PCR followed by Sanger sequencing. However,
in one sample a mutation detected by CADMA,Figure 3 Examples from screening of mCRC samples using the c.38 G
variation in the c.38 G > A CADMA assay compared to any of the other CA
analysis). No heteroduplexes, which melt between 71 and 74°C, can be obs
difference graph. Sample ID 2 deviates more from the wild-type replicates
to 81°C. This should not be interpreted as a c.38 G > T mutation, since noTaqMan, and the Therascreen kit was not detected by
COLD-PCR. Therefore, it is likely that the TheraScreen
kit gave false positive results in two cases (c.34 G > A in
sample ID 65 and c.35 G > A in samples ID 73) and false
negative results in two cases (c.38 G > A in sample ID
91 and c.35 G > A in sample ID 96). Nevertheless,
mCRC patients are pro tem only classified as mutation
positive or negative for selection of treatment groups.
Therefore, only one (sample ID 73) of the 100 patients
studied is likely to have been misclassified. However, as
previously mentioned, evidence is now present that
patients harboring the codon 13 c.38 G > A mutation
may benefit from anti-EGFR treatment [4,5,14]. False
positive and negative results have previously been
observed when using the TheraScreen kit in the order
1-2% [16].
We used 50 ng of DNA in the reactions, but it is likely
that the CADMA assays will perform equally well using
25 ng or less DNA, which we have shown in a study of
BRAF mutations in FFPE cutaneous malignant mela-
noma samples [13].
Many different methods have been developed with the
goal of increasing the analytical sensitivity of mutation
testing, however, increased sensitivity often comes with
the cost of lower accuracy, increased complexity, and> T CADMA assay. The wild-type mCRC samples showed more
DMA assays. A. The derivative of the raw melting data (melt curve
erved in any of the wild-type mCRC samples. B. Normalized HRM
than the standard containing 1% mutant alleles from approximately 79
heteroduplexes are present.
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nation of mutation specific PCR primers and Scorpion
probes, and is relatively expensive and labor-intense
compared to most other methods employed for KRAS
mutation detection [8]. CADMA uses HRM analysis to
determine mutation status, which can be performed in a
closed tube format without the use of any labeled oligo-
nucleotides. HRM has been used for a range of different
applications in molecular diagnostics due to its cost-
effectiveness and convenience [18]. Compared to the
TheraScreen kit and the TaqMan based assay, CADMA
does not require a control assay as the real-time PCR
data serves as a control for the quality of the sample,
and thus the mutation status can be determined directly
after a single run. However, scoring the samples of un-
known mutation status is not always straightforward as
visual inspection of both the derivative of the raw data
(melt curve analysis) and the normalized HRM and dif-
ference graphs (high resolution melting analysis) may be
needed for correct interpretation of the melting data.
The CADMA assays presented here have not been
optimized to perform at a specific annealing temperature,
which would have been an advantage as one sample then
could be tested for all seven mutations in a single run.
However, this may be achieved by changing the concen-
tration of the overlapping primer and/or by designing
new mutation specific primers. Incorporation of locked
nucleic acids (LNAs) in the mutation specific primers
may also make this task easier as the temperature win-
dow, where the mutation specific primer distinguish well
between mutated and wild-type sequences, may be
expanded. It may also be possible to multiplex CADMA
assays while still being able to distinguish between
different mutations, if one mutation specific primer
introduces melting temperature decreasing mutations
in the resulting mutated amplicon, and another muta-
tion specific primer introduces melting temperature
increasing mutations in the other resulting mutated
amplicon.
The possibility to detect low or moderate abundance
mutations is important in many different aspects of
molecular diagnostics [19]. The mutation to be detected
is often well characterized as is the case for KRAS muta-
tions and other mutations in genes such as BRAF, EGFR,
and PIK3CA. However, when the mutation to be detected
with high sensitivity is unknown, other methods such as
COLD-PCR [7] or Ice-COLD-PCR [20] followed by
sequencing or pyrosequencing is recommended. Ice-
COLD-PCR uses a synthetic wild-type-specific oligo-
nucleotide reference sequence (RS), which is slightly
shorter than the length of the PCR amplicon, so that
it obstructs primer binding, and thereby inhibits amplifi-
cation of wild-type alleles when using a five step PCR
as described [20]. The RS contains a 3’-phosphatemodification to prevent polymerase extension, and
should be used together with a polymerase that lacks 5’-
to 3’-exonuclease activity to prevent potential problems
by its hydrolysis. The advantage of Ice-COLD-PCR is
that the RS can be relatively long compared to the use of
short wild-type-blocking oligonucleotides, which can be
used without COLD-PCR [21], thereby allowing sensitive
screening for unknown mutations of longer DNA
sequences. Wild-type-blocking oligonucleotides which
contain LNAs have been used to further increase the
sensitivity of BRAF and KRAS mutation detection in
Wild-type blocking PCR (WTB-PCR) [22,23]. Though
WTB-PCR has proven to be highly sensitive, it is not
performed in a closed-tube format, as sequencing of
the PCR product is necessary.
Conclusions
In conclusion, CADMA may improve KRAS mutation
screening in mCRC. The use of an overlapping primer,
which competes with the mutation specific primer for
target binding may reduce or eliminate false amplifica-
tion otherwise often observed in allele-specific PCR. In
addition, the robust amplification of samples containing
low abundance mutations provided by the overlapping
primer may prevent false negative results. CADMA is
performed in a closed tube format and mutation status
can be determined directly by HRM analysis.
Additional files
Additional file 1: Figure S1. The analytical sensitivity and specificity of
the CADMA assays performed using the Rotorgene Q. Ten
wild-type replicates were run together with a standard dilution series of
mutant alleles from cell lines carrying the relevant mutations in a
wild-type background (50%, 10%, 1%, and 0.5%) in triplicates. The three
replicates of the 0.5% standard could all be distinguished from ten
wild-type replicates in all assays. A. The c.34 G > A CADMA assay. B. The
c.38 G > A CADMA assay. C. The c.35 G > A CADMA assay. D. The c.34
G > C CADMA assay. E. The c.35 G > T CADMA assay. F. The c.34 G > T
CADMA assay.
Additional file 2: Table S1. Overview of the results from screening 100
mCRC samples using the TheraScreen kit and CADMA. A TaqMan based
assay and COLD-PCR followed by sequencing were used to test samples
for which the TheraScreen kit and CADMA did not give the same result.
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